OAM
NVO

Oppenheimer Asset Management’s Novo Nordisk NVO Stock Holding History

Oppenheimer Asset Management’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$30.7M Buy
836,460
+205,055
+32% +$9.72M 0.35% 67
2025
Q4 		$32.1M Buy
631,405
+66,398
+12% +$3.4M 0.4% 57
2025
Q3 		$31.4M Buy
565,007
+71,283
+14% +$4.17M 0.34% 65
2025
Q2 		$34.1M Buy
493,724
+23,159
+5% +$1.58M 0.39% 56
2025
Q1 		$32.7M Buy
470,565
+69,545
+17% +$5.74M 0.41% 55
2024
Q4 		$34.5M Buy
401,020
+7,786
+2% +$842K 0.42% 49
2024
Q3 		$46.8M Buy
393,234
+3,758
+1% +$501K 0.56% 35
2024
Q2 		$55.6M Buy
389,476
+44,981
+13% +$5.96M 0.71% 20
2024
Q1 		$44.2M Sell
344,495
-57,561
-14% -$6.85M 0.65% 28
2023
Q4 		$41.6M Buy
402,056
+6,808
+2% +$673K 0.58% 37
2023
Q3 		$35.9M Buy
395,248
+82,836
+27% +$7.3M 0.55% 39
2023
Q2 		$25.3M Sell
312,412
-11,622
-4% -$949K 0.37% 56
2023
Q1 		$25.8M Sell
324,034
-107,410
-25% -$7.62M 0.4% 55
2022
Q4 		$29.2M Sell
431,444
-34,894
-7% -$2.05M 0.47% 46
2022
Q3 		$23.2M Buy
466,338
+12,086
+3% +$647K 0.41% 54
2022
Q2 		$25.3M Sell
454,252
-18,382
-4% -$1.02M 0.42% 52
2022
Q1 		$26.2M Buy
472,634
+4,496
+1% +$231K 0.37% 59
2021
Q4 		$26.2M Buy
468,138
+5,752
+1% +$312K 0.35% 59
2021
Q3 		$22.2M Sell
462,386
-133,530
-22% -$6.46M 0.32% 70
2021
Q2 		$25M Buy
595,916
+132
+0% +$5.12K 0.36% 59
2021
Q1 		$20.1M Buy
595,784
+57,078
+11% +$2.03M 0.31% 67
2020
Q4 		$18.8M Buy
538,706
+33,144
+7% +$1.15M 0.31% 70
2020
Q3 		$17.6M Buy
505,562
+32,410
+7% +$1.08M 0.34% 62
2020
Q2 		$15.5M Sell
473,152
-33,490
-7% -$1.07M 0.32% 70
2020
Q1 		$15.3M Buy
506,642
+47,396
+10% +$1.41M 0.37% 62
2019
Q4 		$13.3M Buy
459,246
+18,374
+4% +$509K 0.28% 81
2019
Q3 		$11.4M Buy
440,872
+38,678
+10% +$978K 0.25% 90
2019
Q2 		$10.3M Buy
402,194
+45,000
+13% +$1.11M 0.23% 100
2019
Q1 		$9.34M Buy
357,194
+45,618
+15% +$1.12M 0.21% 122
2018
Q4 		$7.18M Buy
311,576
+14,012
+5% +$311K 0.18% 133
2018
Q3 		$7.01M Buy
297,564
+78,098
+36% +$1.91M 0.16% 163
2018
Q2 		$5.06M Buy
219,466
+16,650
+8% +$396K 0.12% 206
2018
Q1 		$5M Buy
202,816
+61,528
+44% +$1.62M 0.13% 205
2017
Q4 		$3.4M Hold
141,288
– – 0.09% 266
2017
Q3 		$3.4M Buy
141,288
+35,610
+34% +$805K 0.09% 268
2017
Q2 		$2.27M Buy
105,678
+24,066
+29% +$486K 0.06% 329
2017
Q1 		$1.4M Buy
+81,612
New +$1.42M 0.04% 454

Other funds holding NVO

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DAM
Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Oppenheimer Asset Management's NVO Position: Q1 2026 in Review

Oppenheimer Asset Management increased its Novo Nordisk (NVO) stake by 32% in Q1 2026, buying an estimated $9.72M and bringing the position to 836,460 shares worth $30.7M. The position accounts for 0.35% of the portfolio, ranked #67.

Oppenheimer Asset Management first reported a position in NVO in Q1 2017 and has held it in 37 quarters since. The position peaked at $55.6M in Q2 2024. 1,272 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

  • Oppenheimer Asset Management held 836,460 shares of Novo Nordisk worth $30.7M as of Q1 2026.
  • Oppenheimer Asset Management bought 205,055 Novo Nordisk shares in Q1 2026, an estimated $9.72M.
  • Novo Nordisk made up 0.35% of Oppenheimer Asset Management's portfolio in Q1 2026, its #67 holding.
  • Oppenheimer Asset Management first reported a position in Novo Nordisk in Q1 2017 and has held it in 37 quarters since.
  • Oppenheimer Asset Management's Novo Nordisk position peaked at $55.6M in Q2 2024.
  • 1,272 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on Oppenheimer Asset Management's 13F filing for Q1 2026, filed 24 Apr 2026.